Search details
1.
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.
Cancer Immunol Immunother
; 73(2): 38, 2024 Jan 30.
Article
in English
| MEDLINE | ID: mdl-38289361
2.
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Ann Surg Oncol
; 31(6): 3872-3879, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38353798
3.
Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en-bloc transurethral resection.
Histopathology
; 2024 Mar 13.
Article
in English
| MEDLINE | ID: mdl-38477374
4.
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy.
BJU Int
; 2024 Apr 24.
Article
in English
| MEDLINE | ID: mdl-38659099
5.
Impact of timing of urinary drainage on clinical outcomes in patients with obstructive pyelonephritis associated with upper urinary tract stones: a propensity score-matched analysis.
World J Urol
; 42(1): 147, 2024 Mar 13.
Article
in English
| MEDLINE | ID: mdl-38478082
6.
Third nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2020 and 2021: Antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus.
J Infect Chemother
; 30(4): 277-285, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38242285
7.
Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections.
J Infect Chemother
; 2024 Apr 06.
Article
in English
| MEDLINE | ID: mdl-38588797
8.
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Int J Clin Oncol
; 29(2): 213-221, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38103156
9.
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Int J Clin Oncol
; 29(5): 612-619, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38430304
10.
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
Int J Clin Oncol
; 2024 Apr 06.
Article
in English
| MEDLINE | ID: mdl-38582807
11.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 545-550, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38517658
12.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol
; 29(5): 535-544, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38494578
13.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(4): 355-362, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38353907
14.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 2024 Apr 23.
Article
in English
| MEDLINE | ID: mdl-38649648
15.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 551-558, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38526621
16.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 559-563, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38538963
17.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 Apr 05.
Article
in English
| MEDLINE | ID: mdl-38578596
18.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 May 02.
Article
in English
| MEDLINE | ID: mdl-38696053
19.
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
Int J Clin Oncol
; 29(1): 55-63, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37863996
20.
A retrospective study of pediatric renal trauma: A single-center experience in Japan.
Int J Urol
; 31(1): 51-55, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37839824